home / stock / xomap / xomap articles

XOMAP Articles, XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

Stock Information
Company Name: XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
Stock Symbol: XOMAP
Market: NASDAQ
Website: xoma.com
Menu
XOMAP XOMAP Quote XOMAP Short XOMAP News XOMAP Articles XOMAP Message Board
Get XOMAP Alerts

News, Short Squeeze, Breakout and More Instantly...
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ | Benzinga

EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today that member...
XOMA Corporation Announces Closing of Tender Offer | Benzinga

EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company"), a biotechnology royalty aggrega...

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. | Benzinga

EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (("XOMA" or the "Company",...

XOMA to Present at Upcoming Investor Conferences in March | Benzinga

EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today members of...
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right | Benzinga

EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) announced today it has entered an agreement to acquire Kinn...

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition | Benzinga

XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial sales and a signif...

FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx | Benzinga

EMERYVILLE, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today that based...
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors | Benzinga

EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today the Board ...

XOMA Announces Stock Repurchase Program of up to $50 Million | Benzinga

EMERYVILLE, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, today announced its Board ...

XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties | Benzinga

Low-cost financing capitalizes on XOMA's $14 million acquisition of VABYSMO® (faricimab) royalties in 2021 Proceeds expected to be used...
Next 10